$12.99 Million in Sales Expected for Antares Pharma, Inc. (NASDAQ:ATRS) This Quarter

Equities analysts predict that Antares Pharma, Inc. (NASDAQ:ATRS) will report $12.99 million in sales for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Antares Pharma’s earnings, with estimates ranging from $11.64 million to $14.09 million. Antares Pharma reported sales of $12.23 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 6.2%. The firm is expected to announce its next quarterly earnings results on Tuesday, August 8th.

According to Zacks, analysts expect that Antares Pharma will report full-year sales of $12.99 million for the current fiscal year, with estimates ranging from $49.19 million to $58.90 million. For the next year, analysts anticipate that the company will post sales of $98.18 million per share, with estimates ranging from $80.50 million to $135.64 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Antares Pharma.

Antares Pharma (NASDAQ:ATRS) last released its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.01. The company had revenue of $12.01 million during the quarter, compared to analyst estimates of $12.10 million. Antares Pharma had a negative return on equity of 45.05% and a negative net margin of 41.26%.

ATRS has been the subject of a number of recent research reports. Vetr raised shares of Antares Pharma from a “hold” rating to a “buy” rating and set a $3.30 price objective for the company in a research report on Wednesday, July 5th. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Antares Pharma in a research report on Friday, June 23rd. Raymond James Financial, Inc. started coverage on shares of Antares Pharma in a research report on Thursday, April 20th. They set a “strong-buy” rating and a $4.30 price objective for the company. Finally, Chardan Capital started coverage on shares of Antares Pharma in a report on Friday, June 23rd. They issued a “buy” rating and a $5.00 target price for the company. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $3.50.

TRADEMARK VIOLATION WARNING: This article was posted by [[site]] and is the sole property of of [[site]]. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at [[permalink]].

Shares of Antares Pharma (ATRS) traded down 3.51% during trading on Wednesday, reaching $3.02. The company’s stock had a trading volume of 1,441,861 shares. The firm’s 50-day moving average price is $3.02 and its 200-day moving average price is $2.68. Antares Pharma has a one year low of $0.98 and a one year high of $3.37. The company’s market capitalization is $470.90 million.

In other Antares Pharma news, insider Fred M. Powell acquired 130,000 shares of the company’s stock in a transaction dated Friday, June 9th. The shares were purchased at an average cost of $2.79 per share, for a total transaction of $362,700.00. Following the completion of the purchase, the insider now owns 331,434 shares in the company, valued at $924,700.86. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 11.60% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in ATRS. BlueCrest Capital Management Ltd purchased a new stake in shares of Antares Pharma during the first quarter valued at $431,000. Renaissance Technologies LLC increased its stake in shares of Antares Pharma by 6.9% in the fourth quarter. Renaissance Technologies LLC now owns 2,859,341 shares of the specialty pharmaceutical company’s stock valued at $6,662,000 after buying an additional 185,000 shares during the period. M&T Bank Corp purchased a new stake in shares of Antares Pharma during the first quarter valued at $227,000. Laurion Capital Management LP purchased a new stake in shares of Antares Pharma during the first quarter valued at $1,373,000. Finally, Wells Fargo & Company MN increased its stake in shares of Antares Pharma by 21.6% in the first quarter. Wells Fargo & Company MN now owns 767,600 shares of the specialty pharmaceutical company’s stock valued at $2,180,000 after buying an additional 136,600 shares during the period. Hedge funds and other institutional investors own 32.04% of the company’s stock.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com